Education
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (GB:0UJF)
:0UJF
0UJF Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$15.41 - C$15.41
Previous CloseN/A
Volume0.00
Average Volume (3M)632.00
Market Cap
C$1.62B
Enterprise ValueC$806.73M
Total Cash (Recent Filing)$64.46M
Total Debt (Recent Filing)$88.54M
Price to Earnings (P/E)284.8
BetaN/A
Next Earnings
May 01, 2025EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding137,339,020
10 Day Avg. Volume265
30 Day Avg. Volume632
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.97
Price to Cash Flow (P/CF)9.70
P/FCF Ratio9.30
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.90
Enterprise Value/Ebitda28.20
Forecast
1Y Price Target
C$14.08Price Target Upside-8.65% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Aurinia Pharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalAurinia announced that the Japanese Health Authorities have approved Lupkynis for the treatment of lupus nephritis.
Revenue GrowthAurinia reported in line 4Q-2024 results, with Lupkynis product revenue increasing 36% year over year.
Bears Say
Competitive LandscapeNumerous anti-APRIL/BAFF therapeutics are in development, some of which are nearing commercialization, thus the competitive landscape remains fierce.
---
Options Prices
Currently, No data available
---
Ownership Overview
8.71% Insiders
5.42% Mutual Funds
1.25% Other Institutional Investors
78.42% Public Companies and Individual Investors
0UJF FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest share price was C$15.41 and its highest was C$15.41 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Aurinia Pharmaceuticals’s market cap is C$1.62B.
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is May 01, 2025 which is in 50 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Aurinia Pharmaceuticals released its earnings results on Feb 27, 2025. The company reported C$0.014 earnings per share for the quarter, beating the consensus estimate of -C$0.023 by C$0.037.
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Overvalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate is 0.14.
How many shares outstanding does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals has 137,339,020 shares outstanding.
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Aurinia Pharmaceuticals reported an EPS of C$0.014 in its last earnings report, beating expectations of -C$0.023. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0UJF
---
Aurinia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$14.08 (-8.65% Downside)
C$14.08 (-8.65% Downside)
Blogger Sentiment
Bullish
GB:0UJF Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $6.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.46%
12-Months-Change
Fundamentals
Return on Equity
1.52%
Trailing 12-Months
Asset Growth
0.47%
Trailing 12-Months
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
---
0UJF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and improved cash flow, driven by the success of LUPKYNIS and operational efficiencies. However, challenges include a decline in gross margin and increased costs related to restructuring. The overall sentiment is balanced with significant achievements and notable challenges.Read More>---
0UJF Revenue Breakdown
90.00% U.S.
10.00% Japan
---
0UJF Stock 12 Month Forecast
Average Price Target
C$14.08
▼(-8.65% Downside)
Technical Analysis
Best Analysts Covering 0UJF
1 Year
1 Year Success Rate
13/22 ratings generated profit
1 Year Average Return
+29.20%
reiterated a buy rating 13 days ago
Copying David Martin PhD's trades and holding each position for 1 Year would result in 59.09% of your transactions generating a profit, with an average return of +29.20% per trade.
---